US to Allow Most Pharma Licensing Deals with China, Draft Rules Show

The US Treasury is drafting rules that would permit most pharmaceutical licensing agreements with Chinese firms, a departure from the Trump administration's broader trade tightening and less restrictive than some lawmakers sought. The move signals a sector-specific carve-out in US-China economic policy, potentially easing regulatory uncertainty for drugmakers. The final scope remains uncertain as the rulemaking process continues.